GLPwatch
Xultophy for Anxiety
liraglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCXultophy (liraglutide) is not FDA-approved for anxiety, and any use for this condition is off-label or investigational. Research in animal models suggests liraglutide may influence behaviors related to anxiety and depression, but human clinical evidence is limited.
AI summary of the sources below.
| Drug | Xultophy (liraglutide) |
|---|---|
| Condition | Anxiety |
| Approval status | Investigational / off-label |
| Research papers | 18 |
Xultophy is not FDA-approved for anxiety; the research below reflects investigational or off-label study only.
Research on liraglutide for anxiety (18)
- Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.
- Liraglutide attenuate central nervous inflammation and demyelination through AMPK and pyroptosis-related NLRP3 pathway.
- Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials.
- Liraglutide attenuates the depressive- and anxiety-like behaviour in the corticosterone induced depression model via improving hippocampal neural plasticity.
- Prevention of pentylenetetrazole-induced kindling and behavioral comorbidities in mice by levetiracetam combined with the GLP-1 agonist liraglutide: Involvement of brain antioxidant and BDNF upregulating properties.
- Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality.
- Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.
- Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis.
- The GLP-1 analog, liraglutide prevents the increase of proinflammatory mediators in the hippocampus of male rat pups submitted to maternal perinatal food restriction.
- Liraglutide for psychiatric disorders: clinical evidence and challenges.
- Liraglutide modulates GABAergic signaling in rat hippocampal CA3 pyramidal neurons predominantly by presynaptic mechanism.
- GLP-1 agonist Liraglutide prevents MK‑801-induced schizophrenia‑like behaviors and BDNF, CREB, p-CREB, Trk-B expressions in the hippocampus and prefrontal cortex in Balb/c mice.
- Liraglutide Reduces Alcohol Consumption, Anxiety, Memory Impairment, and Synapse Loss in Alcohol Dependent Mice.
- Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit.
- Clinical effectiveness of Liraglutide 3.0 mg and impact of weight loss in improving obesity-related comorbid conditions in King Fahad Medical City, Kingdom of Saudi Arabia: A real-world experience.
- Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide: A vigibase study.
- Mental health changes after 4 months of weight loss treatment with the glucagon-like peptide-1 analogue liraglutide 3.0 mg.
- [Does liraglutide have a place in psychiatry ?]